Friday, September 29, 2023


Biotechnology News Magazine

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced a peer-reviewed article published in Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal.

The study highlights the role of blood plasma proteomic profiling for assessing resistance in non-small cell lung cancer (NSCLC) patients being treated with immune checkpoint inhibitors (ICIs).

Over the last decade, ICIs targeting the PD-1/PD-L1 axis have emerged as standard-of-care treatments for NSCLC. Although ICI therapy achieves impressive long-term survival in some, the overall response rate is modest, ranging from 20-30 percent in NSCLC patients. A significant proportion of patients display innate resistance to ICIs, and many of those who derive initial clinical benefit experience disease progression at a later stage. The mechanisms underlying innate and acquired resistance to ICIs are not yet fully understood.

The study, Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade, focuses on how ICI resistance can be predicted in NSCLC patients through proteomic profiling. The analysis was done using PROphet®, OncoHost’s first-of-its-kind diagnostic platform that combines proteomic analysis with AI to predict patient response to immunotherapy and identify resistance associated processes.

“While ICIs have played a major role in revolutionizing cancer therapy, we are still lacking clear biomarkers to predict resistance in patients being treated with these modalities,” said Dr. Michal Harel, Director of Science and Innovation at OncoHost. “In this study, we have analyzed the largest and deepest plasma proteome dataset for NSCLC patients receiving ICI-based treatment published so far, revealing a predictive signature for response to treatment comprised of two proteins and two clinical parameters using our AI-powered PROphet platform. In addition, using bioinformatic tools, we have identified 3 subtypes of patients based on their plasma proteome, each subtype with distinct clinical and functional characteristics. Altogether, these results have the power to create a paradigm shift in truly understanding and overcoming resistance to cancer by characterizing systemic proteomic changes along ICI-based therapy.”

The paper was authored by a team of Israeli and international scientists and oncologists, including Dr. Michal Harel, Prof. Yuval Shaked, co-founder and Chief Scientific Advisor at OncoHost, and professor of cell biology and cancer science at the Technion – Israel Institute of Technology, and Prof. Adam Dicker, a leading radiation oncologist at Thomas Jefferson University and Chief Medical Officer at OncoHost. Additional key investigators included Dr. David Carbone, professor of internal medicine and director of the James Thoracic Center, Prof. Jair Bar, Deputy Director, Institute of Oncology at Sheba Medical Center, and Dr. Alona Zer, Head, Department of Medical Oncology at Rambam Health Care Campus.

“This paper highlights continued success in our clinical trial initiatives as we prepare for the upcoming U.S. launch of PROphet,” said Dr. Ofer Sharon, CEO of OncoHost. “We are finally making significant headway in overcoming the long-standing issue in clinical oncology of patient resistance to treatment. The knowledge that PROphet can provide clinicians with is an industry game-changer, and we are excited to be playing a part in transforming cancer patient care. I am proud of our team and look forward to what lies ahead.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine